AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00513071 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

NIH

Sponsor class

Conditions

Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer

Interventions

DRUG: saracatinib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)